Huge phase 3 trial results on Eli Lilly’s new weight loss drug, retatrutide.
People lost 28% of their bodyweight on average (up to 70lbs), in around a year and a half.
#retatrutideHD #glp1HD #elilillyHD #gipHD #glucagonHD #weightlossHD
Louis shares a CBS report on Eli Lilly's retatrutide, a not-yet-approved triple agonist drug, with an average 28% body weight loss (up to 70 lb) in around a year and a half in a large phase 3 trial. Details come from a news segment.
Huge phase 3 trial results on Eli Lilly’s new weight loss drug, retatrutide.
People lost 28% of their bodyweight on average (up to 70lbs), in around a year and a half.
#retatrutideHD #glp1HD #elilillyHD #gipHD #glucagonHD #weightlossHD
Retatrutide, a new weight loss drug not available on the market yet, is showing promising results in trials. Dr. LaPook explains it’s doing much more than what current medications can.